$INSY Form 8-K

Item 8.01 Other Events.On August 26, 2015, Insys Therapeutics, Inc. (the “Company”) received purported service of notice of three inter partes review (“IPR”) petitions filed by a hedge fund with the U.S. Patent and Trademark Office, challenging three of the four Orange Book-listed patents covering Subsys. The Company intends to oppose the request to institute the IPR and, if any of the three petitions are granted, the Company intends to defend the validity of each patent challenged in each IPR.